Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclophosphamide plus bendamustine for GVHD prophylaxis in haploidentical HSCT for acute leukemia
IRCT20140818018842N50Phase 2Recruiting
- Sponsor
- Tehran University of Medical Sciences
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of cyclophosphamide and bendamustine in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), sponsored by Tehran University of Medical Sciences. Started Nov 2025; status: recruiting.
02
Drugs
cyclophosphamidebendamustine
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on IRCT20140818018842N50.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20140818018842N50.